Debt-to-equity in % of Inmune Bio, Inc. from Q3 2019 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Inmune Bio, Inc. quarterly Debt-to-equity history and change rate from Q3 2019 to Q3 2025.
  • Inmune Bio, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 27.9 %, a 40.7% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Inmune Bio, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 27.9 -19.2 -40.7% 30 Sep 2025
Q2 2025 29.8 -18.2 -38% 30 Jun 2025
Q1 2025 33 -13.1 -28.4% 31 Mar 2025
Q4 2024 40.5 +0.64 +1.61% 31 Dec 2024
Q3 2024 47.1 +10.2 +27.7% 30 Sep 2024
Q2 2024 48 +13.4 +38.7% 30 Jun 2024
Q1 2024 46 +14.6 +46.3% 31 Mar 2024
Q4 2023 39.8 +10.7 +36.9% 31 Dec 2023
Q3 2023 36.9 +10.5 +39.7% 30 Sep 2023
Q2 2023 34.6 +10.5 +43.5% 30 Jun 2023
Q1 2023 31.5 +5.25 +20% 31 Mar 2023
Q4 2022 29.1 +7.69 +35.9% 31 Dec 2022
Q3 2022 26.4 +8.81 +50.1% 30 Sep 2022
Q2 2022 24.1 +11.6 +93.3% 30 Jun 2022
Q1 2022 26.2 +21.9 +503% 31 Mar 2022
Q4 2021 21.4 +16.5 +332% 31 Dec 2021
Q3 2021 17.6 +12.9 +275% 30 Sep 2021
Q2 2021 12.5 +7.95 +176% 30 Jun 2021
Q1 2021 4.35 +0.75 +20.8% 31 Mar 2021
Q4 2020 4.95 +1.87 +60.7% 31 Dec 2020
Q3 2020 4.69 +1.41 +43% 30 Sep 2020
Q2 2020 4.52 30 Jun 2020
Q1 2020 3.6 31 Mar 2020
Q4 2019 3.08 31 Dec 2019
Q3 2019 3.28 30 Sep 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.